HHS & Healthcare Contracts Intelligence — October 21, 2026

The delivery order carries a base-plus-options ceiling of $186,449,775, roughly 2.5x the $73,196,564 currently obligated, with a potential end date of 2031-01-31. Exercise of these options would expand the contract's revenue runway well beyond the current funded period.

Approximately 71% of the obligation has been outlayed, indicating active spend and execution on the NIAID clinical monitoring work. Continued outlay growth would confirm performance momentum, while the remaining balance will require further funding increments.

The provided data does not identify a public ticker or the parent's financial statements, so the contract's materiality to any listed equity cannot be quantified. Investors cannot size exposure to this award without the parent's revenue share.

The award was made under full and open competition with no set-aside, so the contractor holds no protected position and recompete pressure applies when the current period ends on 2027-01-31.

The outlay pace and the remaining $22.4M unfunded obligation depend on annual appropriations; a continuing resolution could delay incremental funding for this cost-plus-fixed-fee delivery order.

The single-contract sample means any conclusion about PPD Development LP or the broader clinical research services segment rests on one award, limiting statistical reliability.

Option exercises on the NIAID Clinical Site Monitoring delivery order could extend work through 2031-01-31, adding value toward the $186,449,775 ceiling for PPD Development LP.

The cost-plus-fixed-fee structure with low contract pricing risk supports predictable cost recovery on clinical site monitoring work, aligned with NAICS 541714 and PSC AN12 health R&D services.

The sole award is a NIH/NIAID delivery order for clinical site monitoring, indicating continued federal reliance on contracted clinical research support. The record supports the civilian health R&D services segment but offers no trend comparison.

{"entity" => "Pharmaceutical Product Development, LLC", "reason" => "Parent of PPD Development LP holding a $73,196,564 NIAID clinical monitoring obligation with $186,449,775 in potential option value; public status and revenue share are not disclosed in the data.", "trigger" => "Option exercise ahead of the 2027-01-31 current end date or disclosure of parent public status"}

{"entity" => "NIH/NIAID clinical research funding", "reason" => "The $73,196,564 obligation is funded through annual appropriations, and the remaining $22.4M balance depends on incremental funding.", "trigger" => "FY2027 HHS appropriations resolution or any continuing resolution affecting NIH funding"}